Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
批准号:
10456871
负责人:
CARRIE E BEARDEN
金额:
$133.87万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-07 至 2024-07-31
关键词:
AchievementAcuteAdolescenceAdolescentAdolescent and Young AdultAftercareAgeAmericanAttenuatedBehaviorBehavioralBipolar DisorderCar PhoneCaringCase ManagementClinicalCommunicationConflict (Psychology)DeteriorationDevelopmentDiagnosticDisease remissionDistalEarly InterventionEducationEmotionalEnrollmentEvidence based interventionFamilyFamily RelationshipFamily StudyFunctional disorderIndividualInterventionInterviewLaboratoriesLongitudinal StudiesMeasurementMeasuresMediatingMental disordersMethodologyMoodsOutcomeParentsParticipantPatientsPerceptionPersonsPopulationProblem SolvingPsychosesPsychotic DisordersQuestionnairesRandomizedRandomized Clinical TrialsResearchRiskSamplingSeveritiesSiteSocial FunctioningStructureSymptomsSyndromeTestingTimeTrainingValidationYouthattenuated psychosis syndromebaseblindclinical high risk for psychosiscommunication behaviorconfirmatory clinical trialconfirmatory trialdisorder later incidence preventionevidence baseexperiencefollow-upfunctional outcomeshigh riskimprovedmobile applicationoffspringpreventive interventionprimary outcomeprobandpsychoeducationpsychosis riskpsychosocialpsychotic symptomsrandomized trialrecruitreduce symptomsremote monitoringresponsesecondary outcomeskillsskills trainingsocialsocial engagementsymptom managementtherapy designtreatment as usualyoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
This proposal responds to RFA-MH-18-707, “Confirmatory Efficacy Clinical Trials of Non-Pharmacological
Interventions for Mental Disorders (R01).” Adolescents and young adults at clinical high risk (CHR) for psychosis,
characterized by recent onset or worsening of attenuated positive symptoms (APS), have a 16%-30% risk of
converting to a psychotic disorder in 2 years. In a prior randomized trial in the North American Prodrome
Longitudinal Study (NAPLS) network, we showed that family-focused therapy for clinical high-risk persons (FFT-
CHR) was more effective than brief family education in (a) improving family (offspring/parent) communication
and (b) reducing APS over 6 months, particularly among CHR youth with high baseline scores on a measure of
individual risk of psychosis conversion. Both treatments were associated with reductions in young people's
perceptions of criticism from parents, which in turn were associated with decreases in APS over 12 months.
These findings led us to hypothesize enhanced family communication as a mechanism of action of FFT-CHR.
FFT-CHR consists of 18 sessions in 6 months of psychoeducation, communication training, and problem-solving
skills training. In the present study conducted in 7 NAPLS sites, we will randomly assign 220 CHR individuals
(ages 13-25) and their parent(s) to FFT-CHR or a 6-month Enhanced Care (EC) treatment, consisting of 3 family
educational sessions followed by 5 months of individual support and case management. CHR individuals will be
interviewed and fill out questionnaires regarding APS (primary outcome) and social functioning (secondary)
every 6 months over 18 months. We will examine behavioral targets indicative of improved family relationships:
reductions in proportion of critical-conflictual statements and increases in proportion of calm-constructive
statements of parents and CHR offspring in laboratory family interactional assessments conducted at baseline
and end of treatment (6 months). We will also capture granular changes in targets and outcomes through remote
monitoring: CHR participants in both conditions will enroll in a newly developed mobile phone app to facilitate
weekly proband ratings of perceived criticism, appraisals of family interactions, and primary and secondary
outcomes. We hypothesize that (1) youth/young adults in FFT-CHR will show greater improvements in APS than
those in EC in 6 months; (2) improvements in parent and offspring communication by 6 months will be associated
with downstream improvements in APS and social functioning over 18 months; and improvements in parent and
offspring communication by 6 months will mediate the relationship between treatment condition and changes in
primary and secondary outcomes over 18 months. We hypothesize that individuals who are at higher baseline
risk of psychosis conversion will show more improvement in targets and primary and secondary outcomes in
FFT-CHR than EC, compared to those at lower conversion risk. The involvement of 7 collaborative NAPLS sites
with complementary expertise will assure accelerated recruitment of the sample, diagnostic reliability, sample
diversity, and treatment exportability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding Rare Genetic Variation and Disease Risk: A Global Neurogenetics Initiative
-
批准号:10660098
-
项目类别:
-
资助金额:$62.97万
-
财政年份:2023
-
负责人:CARRIE E BEARDEN
-
依托单位:
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
-
批准号:10256074
-
项目类别:
-
资助金额:$170.5万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
ProNET: Psychosis-Risk Outcomes Network
-
批准号:10093852
-
项目类别:
-
资助金额:$1086.11万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
-
批准号:10041429
-
项目类别:
-
资助金额:$147.75万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
ProNET: Psychosis-Risk Outcomes Network
-
批准号:10440486
-
项目类别:
-
资助金额:$1591.81万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
ProNET: Psychosis-Risk Outcomes Network
-
批准号:10464673
-
项目类别:
-
资助金额:$211.59万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
ProNET: Psychosis-Risk Outcomes Network
-
批准号:10625429
-
项目类别:
-
资助金额:$1163.63万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
-
批准号:10674012
-
项目类别:
-
资助金额:$92.23万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
ProNET: Psychosis-Risk Outcomes Network
-
批准号:10256743
-
项目类别:
-
资助金额:$1262.37万
-
财政年份:2020
-
负责人:CARRIE E BEARDEN
-
依托单位:
3/9 Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders
-
批准号:10083537
-
项目类别:
-
资助金额:$7.19万
-
财政年份:2019
-
负责人:CARRIE E BEARDEN
-
依托单位:
3/9 Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders
-
批准号:10600822
-
项目类别:
-
资助金额:$26.05万
-
财政年份:2019
-
负责人:CARRIE E BEARDEN
-
依托单位:
3/9 Dissecting the effects of genomic variants on neurobehavioral dimensions in CNVs enriched for neuropsychiatric disorders
-
批准号:9761822
-
项目类别:
-
资助金额:$18.86万
-
财政年份:2019
-
负责人:CARRIE E BEARDEN
-
依托单位:
Neurobiological basis of dysconnectivity in a genetic risk model of psychosis
-
批准号:9791354
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2018
-
负责人:CARRIE E BEARDEN
-
依托单位:
Genetics of Severe Mental Illness
-
批准号:9302004
-
项目类别:
-
资助金额:$123.5万
-
财政年份:2017
-
负责人:CARRIE E BEARDEN
-
依托单位:
Genetics of Severe Mental Illness
-
批准号:9892048
-
项目类别:
-
资助金额:$110.09万
-
财政年份:2017
-
负责人:CARRIE E BEARDEN
-
依托单位:
Integration of Five Large-Scale Neuropsychiatric Genetic Datasets under the RDoC Framework
-
批准号:9104227
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2015
-
负责人:CARRIE E BEARDEN
-
依托单位:
Integration of Five Large-Scale Neuropsychiatric Genetic Datasets under the RDoC Framework
-
批准号:8970437
-
项目类别:
-
资助金额:$7.7万
-
财政年份:2015
-
负责人:CARRIE E BEARDEN
-
依托单位:
IDENTIFICATION OF ENDOPHENOTYPES FOR BIPOLAR DISORDER
-
批准号:8363438
-
项目类别:
-
资助金额:$1.01万
-
财政年份:2011
-
负责人:CARRIE E BEARDEN
-
依托单位:
IDENTIFICATION OF ENDOPHENOTYPES FOR BIPOLAR DISORDER
-
批准号:8171053
-
项目类别:
-
资助金额:$1.22万
-
财政年份:2010
-
负责人:CARRIE E BEARDEN
-
依托单位:
Neurofibromatosis Type I as a Model for Therapeutic Neuroadaptation
-
批准号:8116584
-
项目类别:
-
资助金额:$22.87万
-
财政年份:2009
-
负责人:CARRIE E BEARDEN
-
依托单位:
海外基金